Myosin Therapeutics, Inc., a biotechnology company developing novel therapies for cancer and neurological disorders, has closed its second seed funding round, raising over $3 million to supplement significant investment from the National Institutes of Health.

Myosin Therapeutics, Inc.是一家致力于开发癌症和神经系统疾病新疗法的生物技术公司，该公司已完成第二轮种子融资，筹集了超过 300 万美元，以补充来自美国国立卫生研究院的重大投资。

The seed funding round was led by repeat investors, DeepWork Capital, Florida Opportunity Fund, and Mint12 Pharma, along with Dynagrow Capital, the private investment management affiliate of Fred Hassan. Also participating in the round were Mayo Clinic Ventures and The Sontag Innovation Fund, which is focused on accelerating solutions to change the standard of care in brain cancer..

种子轮融资由重复投资者 DeepWork Capital、佛罗里达机会基金和 Mint12 Pharma 领投，Dynagrow Capital（Fred Hassan 的私人投资管理附属机构）也参与其中。此外，梅奥诊所风险投资公司和专注于加速改变脑癌护理标准解决方案的 Sontag 创新基金也参与了本轮融资。